Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Non-Small-Cell Lung Carcinoma Clinical Trial

Official title:

A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00078455
• Other study ID #: ILX651-231
• Status: Completed
• Phase: Phase 2
• First received: February 25, 2004
• Last updated: March 4, 2015
• Start date: December 2003
• Est. completion date: August 2005

Study information

• Verified date: March 2015
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered intravenously (IV) daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate. The secondary objectives are to determine the progression free survival, duration of response, time to tumor progression, survival, safety/tolerability of ILX651, and to evaluate pharmacokinetic profile.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed locally advanced or metastatic NSCLC previously treated with 2 prior chemotherapy regimens (not including prior adjuvant therapy for stage I or II disease).

• Disease recurrence or progression after prior therapy with a platinum-based and a taxane-based regimen, given either concurrently or separately.

• Measurable disease. Measurable lesions should be outside the field of radiation. Where measurable lesions are within a previously irradiated field, there must be objective evidence of progression of the lesion prior to patient enrollment.

• Male or female patients greater than or equal to 18 years of age.

• ECOG performance status of 0 or 1.

• Must have adequate organ and immune system function as indicated by the following laboratory values, obtained less than or equal to 2 weeks prior to registration: A. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 1,000,000,000. B. Hemoglobin greater than or equal to 9.0 g/dL. C. Platelet count greater than or equal to 100 x 1,000,000,000/L. D. Serum creatinine or calculated creatinine clearance less than or equal to 1.5 mg/dL or greater than or equal to 60 mL/min. E. Serum total bilirubin within limits of normal values. F. AST and ALT less than or equal to 2 times the upper limit of normal (ULN). G. Alkaline phosphatase within limits of normal values

• Anti-cancer therapy, major surgery, or irradiation must have been completed at least 3 weeks before enrollment in this study. Patient must have recovered from the acute side effects incurred as a result of previous therapy.

• Female patients with childbearing potential must have a negative pregnancy test within 7 days of study enrollment. Men and women of reproductive potential must use an effective contraceptive method while enrolled in the study.

• Signed informed consent (includes HIPAA authorization).

Exclusion Criteria:

• Patients with uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment, or patients with cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification.

• Previously treated with > 2 prior chemotherapy regimens for advanced or metastatic disease.

• Prior radiotherapy to the only site of measurable disease.

• Known hypersensitivity to study drug or its analogs.

• Use of investigational agents within previous 30 days.

• Known, active infection, or known HIV positive or presence of an AIDS related illness.

• Active secondary malignancy except minor skin cancers.

• Presence of symptomatic active brain metastases, including leptomeningeal involvement.

• Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results.

• Pregnant or lactating females.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small-Cell Lung Carcinoma

Intervention

Drug:
• ILX651

Locations

Country	Name	City	State
United States	Anshutz Cancer Pavillion	Aurora	Colorado
United States	US Oncology / Texas Cancer Center	Dallas	Texas
United States	US Oncology / Central Indiana Cancer Centers	Indianapolis	Indiana
United States	Joe Arrington Cancer Center	Lubbock	Texas
United States	Sarah Cannon Cancer Center	Nashville	Tennessee
United States	Hematology and Oncology Specialists	New Orleans	Louisiana
United States	US Oncology / Ocala Oncology	Ocala	Florida
United States	Cancer Institute Medical Group	Santa Monica	California
United States	US Oncology/ Arizona Clinical Research Center	Tucson	Arizona
United States	US Oncology / Tyler Cancer Center	Tyler	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States,